Ac225-DOTA-M5A
/ City of Hope, National Cancer Institute - Bethesda
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
September 17, 2025
Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers
(clinicaltrials.gov)
- P1 | N=20 | Recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Aug 2025 ➔ Jul 2026 | Trial primary completion date: Aug 2025 ➔ Jul 2026
Trial completion date • Trial primary completion date • Oncology
March 06, 2024
Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers
(clinicaltrials.gov)
- P1 | N=20 | Recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Mar 2024 ➔ Aug 2025 | Trial primary completion date: Mar 2024 ➔ Aug 2025
Metastases • Trial completion date • Trial primary completion date • Oncology
June 09, 2022
Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Positive Advanced Colorectal Cancer
(clinicaltrials.gov)
- P1 | N=20 | Recruiting | Sponsor: City of Hope Medical Center | Not yet recruiting ➔ Recruiting
Enrollment open • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor
1 to 3
Of
3
Go to page
1